Open AccessThyroid‐associated orbitopathy developed during hormone replacement therapy
Author(s) -
Øgard Christina Gerlach,
Øgard Carsten,
Almdal Thomas Peter
Publication year - 2001
Publication title -
acta ophthalmologica scandinavica
Language(s) - English
Resource type - Journals
eISSN - 1600-0420
pISSN - 1395-3907
DOI - 10.1034/j.1600-0420.2001.079004426.x
Subject(s) - medicine , estrogen , thyroid , hormone replacement , hormone replacement therapy (female to male) , estrogen therapy , hormone therapy , hormone , endocrinology , cancer , breast cancer , testosterone (patch)
. Thyroid‐associated orbitopathy (TAO) developed in relation to estrogen combined with progesterone therapy has not been reported previously. We report a case of a 56‐year‐old postmenopausal woman who during estrogen/progesterone treatment developed signs and symptoms of orbitopathy. The patient had no previous history of autoimmune‐ or thyroid disorders. The initial eye symptoms disappeared after withdrawal of hormone replacement therapy. Five years later estrogen/progesterone treatment was re‐instituted. The patient had relapse of orbitopathy. The hormones were discontinued and the eye symptoms disappeared again. This suggests that estrogen and/or progesterone could be of some pathogenetic importance in the induction of orbitopathy